|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
|
18193168 |
2008 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
|
19917957 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor gene related to cylindroma and is negative regulator of NF-kappaB.
|
16627981 |
2006 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD in ubiquitin signaling and tumor pathogenesis.
|
16713556 |
2006 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumour-suppressor gene that is mutated in a benign skin tumour syndrome called cylindromatosis.
|
19893491 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD(C/S) tumors are also characterized by their elevated proliferation rate and decreased apoptosis.
|
20838385 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a deubiquitinating enzyme that exerts a tumor suppressive function.
|
27570065 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor and a deubiquitination enzyme.
|
28840581 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD lysine 63 deubiquitinase (CYLD) was originally identified as a tumor suppressor that is mutated in familial cylindromatosis.
|
29344161 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD.
|
26969893 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes.
|
31624251 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.
|
25130432 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
DNA analysis of tumour tissue showed loss of heterozygosity for the cylindromatosis CYLD1 locus.
|
9783709 |
1998 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Expression of the tumor suppressor CYLD was inhibited by miR-362 in gastric cancer cells; miR-362 levels were inversely correlated with CYLD expression in gastric cancer tissue.
|
24495516 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
For this, we explored the tumor microenvironment for targeted drug delivery and synthesized (temperature and pH responsive) double triggered polymeric nanoparticles by the free radical mechanism and characterized them by DLS and TEM.
|
31549130 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Further in line with these animal data, exogenous expression of CYLD(m) in A431, a human squamous cell carcinoma (SCC) cell line, markedly enhanced cell growth, migration, and subcutaneous tumor growth in an AP1-depdendent manner.
|
21478324 |
2011 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, knockdown of CYLD expression partially counteracted the tumor suppressive effects of miR-362-5p inhibitors.
|
25449782 |
2015 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the tumour suppressor gene CYLD are recognized to be associated with the development of multiple cutaneous cylindromas.
|
29569226 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5<sup>+</sup> B cells through sustained canonical NF-κB signaling.
|
28566736 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established.
|
27775078 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In 1 patient only with 2 spiradenomas, both tumors harbored identical CYLD sequence alterations (c.1112C>A/S371X) in the CYLD gene and both showed loss of heterozygosity on chromosome 16q.
|
22588548 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD.
|
18008375 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In affected families, mutations have been demonstrated in the CYLD gene located on chromosome 16q12-13 and reveal the characteristic attributes of a tumor suppressor.
|
12190880 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer.
|
30631004 |
2019 |